Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 115 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HIV-Infected Children Clear all

Conditions: HIV Infections, Central Nervous System Diseases
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Focus Group, First Intervention Trial, Intervention Trial 2; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Los Angeles, California • New York, New York • Philadelphia, Pennsylvania

Conditions: HIV-1, HIV Infections
Interventions: TMC114, Ritonavir; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Conditions: HIV Infections
Interventions: Tetanus toxoid, Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 25
States / cities: Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more

Conditions: HIV Infections, Hepatitis C
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 20 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Antiretroviral Toxicity
Interventions: Not listed
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: Not listed
Enrollment: 5,169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2025
U.S. locations: 20
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more

Conditions: HIV Infections
Interventions: Delavirdine mesylate; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 1 Month to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 32
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 24 more

Conditions: HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy, Dyslipidemia, Osteoporosis, Osteopenia
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 25 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 36
States / cities: Birmingham, Alabama • Alhambra, California • Long Beach, California + 26 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: Not listed
Enrollment: 1,207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 37
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 24 more

Conditions: HIV Infections
Interventions: Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 49
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 33 more

Conditions: HIV Infections, Pregnancy
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: HIV Infections
Interventions: Needs assessment followed by tailored intervention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 5 Years to 12 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • The Bronx, New York

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: HIV Infections
Interventions: DTG film-coated tablets, DTG granules for suspension, DTG dispersible tablets; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Weeks to 17 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 11 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Months to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more

Conditions: HIV Infections
Interventions: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 11 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more

Conditions: HIV Infections
Interventions: Zidovudine, Zalcitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 44
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 29 more

Conditions: HIV Infections
Interventions: Interferon alfa-2a, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 17 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 6
States / cities: Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Emtricitabine, Stavudine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 2 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 12
States / cities: Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: HIV Infections, Hyperlipidemia
Interventions: Atorvastatin; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: 10 Years to 23 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 11
States / cities: Aurora, Colorado • Miami, Florida • Tampa, Florida + 7 more

Conditions: HIV Infections
Interventions: Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 3 Months to 12 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Fort Lauderdale, Florida + 25 more

Search by objective public record fields.

Central Nervous System Disease in HIV-infected Children on HAART

Integrated Treatment of Marijuana Abuse for HIV+ Youth

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV

Prevalence of Hepatitis C Virus Infection in HIV-Infected Children

Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth

IMPAACT P1074: Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents

A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine

A Study of Zidovudine in HIV-Infected Pregnant Women and Their Children

Pediatric Impact: Promoting Adherence to Medications Among HIV-infected Children

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

A Study of Dideoxycytidine Plus Zidovudine (AZT) in HIV-Infected Children Who Have Taken AZT

The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs